By Brian's Robot0
The prejudgment interest ruling pushes Apple's tab for an Apple Watch pulse-oximetry patent to about $818 million, though Masimo didn't get the 7% rate it wanted.
Apple's bill in its long-running patent fight with Masimo just grew by $184 million. On Monday, October 5, US District Judge James V. Selna in California ordered Apple to pay that amount in prejudgment interest on top of the $634 million a jury awarded Masimo last November, Bloomberg Law reported. MacRumors, 9to5Mac, and AppleInsider have since followed.
That brings the total to roughly $818 million, and post-judgment interest will keep accruing until Apple pays.
Apple argued that awarding interest would amount to a windfall for Masimo. Selna disagreed, citing US Supreme Court guidance that "interest from the time that the royalty payments would have been received merely serves to make the patent owner whole." Put simply, Masimo is being compensated for the years it went without royalties it should have collected.
Masimo didn't get everything it asked for. It wanted interest calculated at a 7% rate, which would have come to about $243 million. Selna instead used Masimo's own borrowing rate, compounded annually from when the infringement began, trimming roughly $59 million from Masimo's figure.
The patent expired in June 2022, so the ruling concerns past Apple Watch sales only. It has no effect on the heart-rate features in current models. Apple has fought the award at each step so far, trying unsuccessfully to overturn or reduce it before Selna upheld the verdict in July.
This damages case is distinct from Masimo's complaint at the US International Trade Commission, which led to a 2023 import ban on certain Apple Watch models. To keep selling those watches in the US, Apple disabled blood oxygen measurement on affected units sold there, then introduced a redesigned version of the feature in 2025.
For more on the lineup, see our Apple Watch coverage.
Get Apple News and rumors in your inbox!